Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers

Annals of Oncology

Volumn 19, Issue 4, 2008, Pages 649-654

  Baak, J P A ^a,b,c   van Diest, P J ^a   Janssen, E A M ^b   Gudlaugsson, E ^b   Voorhorst, F J ^a   van der Wall, E ^a   Vermorken, J B ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Stavanger University Hospital   (Netherlands)

^c UNIVERSITY OF BERGEN   (Norway)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Breast cancer; Mitotic index; Prognosis; Proliferation; Small tumours; Well differentiated cancers

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MITOSIS INDEX; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC THERAPY; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 41549127071     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm535     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Silvestrini R, Daidone MG, Di Fronzo G et al. Prognostic implication of labeling index versus estrogen receptors and tumour size in node-negative breast cancer. Breast Cancer Res Treat 1986; 7: 161-169.
3. Bergers E. van Diest PJ, Baak JPA. Prognostic implications of different cell cycle analysis models of flow cytometric DNA, histograms of 1301 breast cancer patients: Results from the Multicenter Morphometric Mammary Carcinoma Project. Int J Cancer 1997; 74: 266-269.
4. Baak JPA, van Dop H, Kurver PHJ et al. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374-382.
5. Uyterlinde AM, Baak JPA, Schipper NW et al. Prognostic value of morphometric and DNA flow-cytometry features of invasive breast cancers detected by population screening: Comparison with control group of hospital patients. Int J Cancer 1991; 48: 173-181.
6. Clayton F. Pathologic correlates of survival in 378 lymph node-negative Infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991; 68: 1309-1317.
7. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol 2004; 57: 675-681.
8. Thor AD,. Liu S, Moore DH II et al. Comparison of mitotic index, in vitro. bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999; 17: 470-477.
9. Groenendijk RP, Butt P, Noppen CM et al. Mitotic activity index in interval breast cancers. Eur J Surg Oncol 2003; 29: 29-31.
10. Manders P, Bult P, Sweep CG et al. The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy. Breast Cancer Res Treat 2003; 77: 77-84.
11. Meyer JS, Alvarez C, Milikowski C et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advahtages of proliferation index. Mod Pathol 2005; 18 (8): 1067-1078.
12. Volpi A, Bacci F, Paradiso A et al. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol 2004; 17(9): 1038-1044.
13. Baak JP, van Diest PJ, Voorhorst, FJ et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005; 23 (25): 5993-6001.
14. Baak JPA, van Diest PJ, Voorhorst FJ et al. Age dependendy of the prognostic value of the mitotic activity index (MAI) and other characteristics in lymph node-negative breast cancer patients. Eur J Cancer 2007; 43: 527-535.
15. Andre F, Khalil A, Slimane K et al. Mitotic index and benefit of adjuvant anthracyline-based chemotherapy in patients with early breast cancer. J Clin Oncoll 2005; 23 (13): 2996-3000.
16. Amadori O, Nanni O, Marangolo M et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study. J Clin Oncol 2000; 18: 3125-3134.
17. Janssen EAM, van Diest PJ, Søiland H et al. Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years. Cell Oncol 2006; 28: 295-303.
18. Baak JPA, van Diest PJ, Ariens A et al. The multicenter morphometric mammary carcinoma project (MMMMGP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract, 1989; 185: 664-670.
19. van Diest PJ, Baak JPA, Matze-Cok P et al. Reproducibility, of mitosis counting in 2469 breast cancer specimens: Results frorn the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992; 23: 603-607.
20. World Health Organisation. Histologic Typing of Breast Tumours, 2nd edition. Geneva, Switzerland: World Health Organisation 1981.
21. Ellis IO, Schnitt SJ, Sastre-Garau X et al. Invasive breast carcinoma. In Tavassoli FA, Devilee P (eds): Pathology and Genetics of Tumours of the Breast and Female Genital Tract Organs. Lyon, France: IARC Press 2003.
22. Jannink I, van Diest PJ, Baak JPA. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: Classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol 1995; 26: 1086-1092.
23. Volpi A, Nanni O, De Paola F et al. HER-2 expression and cell proliferabon: Prognostic markers in patients with node-negative breast cancer. J Clin Oncol 2003; 21: 2708-2712.
24. Jalava P, Kuopio T, Juntti-Patinen L et al. Ki67 immunohistochemistry: A valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48 (6): 674-682.
25. ChakravarthyAB, Kelley MC, McLaren B et al. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res 2006; 12 (5): 1570-1576.
26. Hayes DF. Prognostic and predictive factors revisited. Breast 2005; 14 (6): 493-499.
27. Hall PA, Going JJ. Predicting the future, a critical appraisal of cancer prognosis studies. Histopathology 1999; 35: 489-494.
28. Baak JP. The framework of pathology: Good laboratory practice by quantitative and molecular methods. J Pathol 2002; 198 (3): 277-283.
29. Michiels S, Koscielny, S, Hill C. Prediction of cancer outcome with microarrays, a multiple random validation strategy. Lancet 2005; 365: 488-492.